An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)
Phase of Trial: Phase IV
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease; Psoriasis; Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms VITALITY
- Sponsors AbbVie
- 19 Jan 2018 Status changed from active, no longer recruiting to completed.
- 26 Oct 2017 Planned End Date changed from 30 Dec 2017 to 31 Dec 2017.
- 26 Oct 2017 Planned primary completion date changed from 30 Dec 2017 to 31 Dec 2017.